SEBI Reg. Investment Advisor

Download App
Help Center Pricing
Money Works 4 Me Logo MoneyWorks4Me
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

INVESTMENT INSIGHTS

Check Before You Invest : Eris Lifesciences Ltd

BSE: 540596 NSE: ERIS ISIN: INE406M01024
  |   Sector:  Healthcare   |   Industry:  Pharmaceuticals & Drugs

Snapshot

Q.1 Which industry/sub-sector does Eris Lifesciences Ltd belong to?
Eris Lifesciences Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.
Q.2 Is Eris Lifesciences Ltd a good quality company?
Eris Lifesciences Ltd is a good quality company, based on a consistently good 10 year financial track record.
Q.3 Is Eris Lifesciences Ltd undervalued or overvalued?
Eris Lifesciences Ltd appears Fair, as its key valuation ratios are in line with their past averages.
Q.4 Is Eris Lifesciences Ltd a good buy now?
Eris Lifesciences Ltd is a good buy now, based on strong price trend analysis suggesting prices may rise. However, you need to check its quality and valuation before making a decision

Performance Analysis

Q.1 Revenue growth of Eris Lifesciences Ltd?
Eris Lifesciences Ltd revenue growth is 44% for FY-2025 , which is above its 5 year CAGR of 21.9% , indicating faster growth.
Q.2 Gross Profit margin of Eris Lifesciences Ltd?
Eris Lifesciences Ltd Gross profit margin which is the profit after deduction of direct costs, is 27.1% for FY-2025 , which is below its 5 year median of 29.6% , indicating decreasing margins.
Q.3 Operating Profit Margin of Eris Lifesciences Ltd?
Eris Lifesciences Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 35.18% for FY-2025 , which is in line with its 5 year median of 35.18% indicating stable margins.
Q.4 Net Profit Margin of Eris Lifesciences Ltd?
Eris Lifesciences Ltd Net Profit Margin is 12.95% for FY-2025 , is below with its 5 year median of 22.2%, indicating decreasing margins.
Current Level Historic Median
Gross Profit Margin 27.1 29.6
Operating Profit Margin 35.18 35.18
Net Profit Margin 12.95 22.2
Q.5 Return on Asset of Eris Lifesciences Ltd?
Eris Lifesciences Ltd Return on Asset is 5.48%, which is below its 5 year historical median of 13.4%, indicating deteriorated asset utilization efficiency.
Q.6 Return on Equity (ROE) of Eris Lifesciences Ltd?
Eris Lifesciences Ltd Return on equity is 13.81% for FY-2025 , which is below its historical median of 18.25%, indicating the business is making worse use of its shareholders capital.
Q.7 Return on capital employed (ROCE) of Eris Lifesciences Ltd?
Eris Lifesciences Ltd Return on capital employed is 13.59% for FY-2025 , which is above its estimated weighted average cost of capital(WACC) 13.5%, indicating value creation.
Q.8 Cash conversion cycle of Eris Lifesciences Ltd?
Eris Lifesciences Ltd Cash conversion cycle is 34 days, above its historical median of 29 days, indicating deteriorated working capital management. However, you need to compare this with its peers in the industry.
Current Level Historic Median
Asset Turnover 0.43 0.63
ROE 13.81 18.25
ROCE 13.59 17.3
Cash Conversion Cycle 34 days 29 days
Q.9 Debt to Equity ratio of Eris Lifesciences Ltd?
Eris Lifesciences Ltd Debt-to-Equity ratio is 0.85 , which is above with the industry average of 0.15 , indicating higher debt levels in the industry.
Q.10 Debt to cash flow from operations of Eris Lifesciences Ltd?
Eris Lifesciences Ltd Debt to cash flow from operations is 2.27 , which is at a moderate level.

Ownership & governance

Q.1 Promoter shareholding and pledge status of Eris Lifesciences Ltd?
Promoters hold 53.92% of the Eris Lifesciences Ltd, with 16.92% of their stake pledged, indicating high pledge risk.

Peer comparison (industry-wise, mcap)

Q.1 Revenue growth of Eris Lifesciences Ltd vs industry peers?
Eris Lifesciences Ltd revenue CAGR is 21.92% , compared to the industry median CAGR of 5.54% , indicating faster growth and gaining its market share.
Profit Metrics
Current Level Industry Median
Revenue 2,893.6 137.1
Gross Profit 784.3 15.1
Operating Profit 1,017 16
Net Profit 375 5.6
Operating Efficiency
Current Level Industry Median
Asset Turnover 0.43 0.8
ROE 13.81 8.91
ROCE 13.59 11.59
Cash Conversion Cycle (days) 34.08 76

Valuation & price assessment

Q.1 Stock return of Eris Lifesciences Ltd over the last decade?
Over the last 5 year(s), the stock has delivered a CAGR of 19.74% based on the current price.
Q.2 What return has the stock given over the last decade?
9Y 5Y 3Y 1Y
Share Price - 19.7% 33.2% 4.7%
Q.3 Valuation ratios of Eris Lifesciences Ltd vs historical?
The current P/E is higher that its historical median.
Q.4 How do the current valuation ratios measure up against the historic numbers and the current industry numbers?
Valuation Ratios Current Historic Median Industry Median
Price to Earnings 47.02 23.13 40.28
Price to Book 5.6 5.22 2.77
Price to Sales 6.62 6.78 2.65
EV to EBITDA 20.29 18.60 15.67

Check more companies

1. Ajanta Pharma
2. JB Chem & Pharma
3. Emcure Pharma
4. Gland Pharma
5. Wockhardt
6. Pfizer
7. Astrazeneca Pharma I
8. Sai Life Sciences
9. Natco Pharma
10. Eris Lifesciences
2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×